Detalhe da pesquisa
1.
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Cell
; 165(2): 317-30, 2016 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27058664
2.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Blood
; 139(8): 1160-1176, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201323
3.
Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
Transfusion
; 62(11): 2334-2348, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239134
4.
Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
BMC Bioinformatics
; 21(1): 333, 2020 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32711453
5.
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Cancer Sci
; 110(11): 3565-3572, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31520559
6.
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Br J Cancer
; 113(7): 1027-34, 2015 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26355232
7.
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
Blood Adv
; 8(9): 2059-2073, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266153
8.
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.
Cancer Med
; 12(20): 20332-20352, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37840445
9.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Nat Biotechnol
; 41(9): 1296-1306, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635380
10.
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Lung Cancer
; 184: 107356, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37660479
11.
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35058326
12.
Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272304
13.
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial.
Clin Cancer Res
; 26(3): 717-725, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727675
14.
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Front Immunol
; 11: 1771, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32922390
15.
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
Leukemia
; 34(12): 3298-3309, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32409691
16.
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.
Nat Cancer
; 1(1): 86-98, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121834
17.
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Cells
; 8(12)2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31779273
18.
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).
Target Oncol
; 11(4): 489-500, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27412031
19.
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Blood Cancer J
; 11(3): 55, 2021 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33712562
20.
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
Leukemia
; 34(1): 317-321, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409922